Recurrent Pericarditis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Recurrent Pericarditis, a syndrome characterized by the reappearance of pericardial inflammation symptoms after a symptom-free interval of 4–6 weeks following an acute pericarditis episode, is a significant medical concern. Various factors, including infections and autoimmune responses, can trigger this condition. The symptoms of recurrent Pericarditis encompass a dull ache, pressure, or stabbing chest pain that intensifies when coughing, taking deep breaths, or lying down. This pain, often mistaken for a heart attack, is alleviated by sitting up and leaning forward. Patients may also experience shortness of breath or difficulty breathing. This syndrome is the most challenging complication of acute Pericarditis, with 20% to 50% of patients experiencing recurrence within 18 months of the initial acute pericarditis episode. This can result in repeated hospitalizations and increased treatment costs. In approximately 85% of cases, the etiology remains idiopathic as it cannot be identified using standard laboratory techniques. Systemic diseases, including lupus erythematosus, Sjögren syndrome, rheumatic arthritis, scleroderma, and systemic vasculitis, among others, are often responsible for many recurrent cases. These diseases are well-known manifestations of recurrent Pericarditis. Consequently, Pericarditis is seldom the primary identified condition but is typically treated as part of the regimen for the accompanying disease. The typical treatment for recurrent Pericarditis involves aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs). If NSAIDs and colchicine fail to achieve complete remission, corticosteroids such as prednisone are prescribed in low to moderate doses.
• In the U.S., recurrent Pericarditis affects 15% to 50% of individuals with Pericarditis, approximately 40,000 people. The condition is most prevalent among males aged 16 to 65 years.

Thelansis’s “Recurrent Pericarditis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Pericarditis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Recurrent Pericarditis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Recurrent Pericarditis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Recurrent Pericarditis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Recurrent Pericarditis, Recurrent Pericarditis market outlook, Recurrent Pericarditis competitive landscape, Recurrent Pericarditis market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)